NCT00941460已完成2 期
Dose-intensified Rechallenge With Temozolomide, One Week On One Week Off Versus Three Weeks On One Week Off in Patients With Progressive or Recurrent Glioblastoma
Prof. Dr. Wolfgang Wick16 个研究点 分布在 3 个国家目标入组 105 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 16
- 主要终点
- Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.
研究概览
简要总结
For patients with progressive or recurrent glioblastoma there is no standard therapy. One strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done by 2 regimens. Aim of this study is to compare these 2 dosing regimens concerning toxicity. In study arm A patients receive temozolomide for one week, followed by a week without temozolomide. In study arm B patients receive temozolomide for three weeks, followed by a week without temozolomide. The regimen that is less toxic will be selected for further evaluations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Progressive or recurrent glioblastoma documented by MRI no earlier than 180 days after first surgery for glioblastoma and no earlier than 90 days after completion of radiotherapy.
- •Histological diagnosis of glioblastoma
- •Tissue available for the determination of MGMT promoter methylation in the primary tumor or from the recurrent tumor if a patient undergoes a surgical procedure at recurrence prior to study entry.
- •Prior treatment with temozolomide administered concomitantly with radiotherapy and at least for two cycles (5/28) as an adjuvant treatment
- •Informed consent
- •Age 18-80 years
- •Karnofsky performance score > 50%
- •Neutrophil counts > 1 500/µl
- •Platelet counts > 100 000/µl
- •Hemoglobin > 10 g/dl
- •Serum creatinin < 1.5-fold upper normal range
- •ASAT or ALAT < 3-fold upper normal range unless attributed to anticonvulsants
- •Alkaline phosphatase < 3-fold upper normal range
- •Women with childbearing potential must have a negative serum pregnancy test ≤14 days prior to study enrollment
- •Willingness to apply contraception according to local requirements (as stated in patient information)
排除标准
- •Progressive or recurrent glioblastoma documented by MRI earlier than 180 days after first surgery for glioblastoma and earlier than 90 days after completion of radiotherapy.
- •Treatment with any chemotherapy other than temozolomide according to the schedule of the EORTC NCIC trial (Stupp et al. N Engl J Med 2005;352:987-996) except that an adjuvant starting dose of 200 mg/m2 and more than 6 cycles of adjuvant temozolomide are allowed
- •Prior systemic or local treatment with DNA-damaging agents, tyrosine kinase inhibitors or anti-angiogenic agents for any cancer
- •Allergy to or other intolerability of temozolomide
- •Unable to undergo MRI
- •Past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation
- •HIV infection
- •Pregnancy
- •Breast feeding
- •Treatment within in any other clinical trial parallel to the treatment phase of the current study
研究组 & 干预措施
one week on one week off
Experimental
One week on temozolomide is followed by a week without temozolomide.
干预措施: Temozolomide in both arms (Drug)
three weeks on, one week off
Experimental
Temozolomide is given over 3 weeks, followed by a week without temozolomide.
干预措施: Temozolomide in both arms (Drug)
结局指标
主要结局
Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.
时间窗: up to one year
次要结局
- progression free survival(up to two years)
研究者
Prof. Dr. Wolfgang Wick
Coordinating Investigator
Heidelberg University
研究点 (16)
Loading locations...
相似试验
招募中
3 期
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated GlioblastomaGlioblastoma, IDH-wildtypeMGMT-Methylated GlioblastomaNCT06419946Vastra Gotaland Region200
终止
1 期
Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to ChemotherapyGlioblastoma Multiforme (WHO Grade IV)Anaplastic Astrocytoma (WHO Grade III)NCT00272870Children's Hospital Medical Center, Cincinnati1
终止
早期 1 期
Evaluating Tumor Pseudoprogression With FLT-PET and MRIGlioblastomaNCT01105988Massachusetts General Hospital2
进行中（未招募）
不适用
Dose Intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma (DIRECTOR)EUCTR2008-006871-60-ATniversity Hospital Heidelberg, Ruprechts-Karl-University Heidelberg166
进行中（未招募）
不适用
Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma - DIRECTORprogressive or recurrent glioblastoma after first surgery for glioblastoma and after completion of radiotherapyMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2008-006871-60-DEniversity Hospital Heidelberg, Ruprechts-Karl-University Heidelberg166